IceCure Medical Ltd ICCM
0.80 USD -0.20 (-19.71%)
Regular-session close
0.85 +0.05 +6.23%
After hours · Nov 20, 4:00 PM ET
0.7611 Day range 0.9576
0.681 52-week range 21.90
- YTD
- -95.63%
- 1 year
- -95.89%
News
fool.com IceCure: 3 Key Takeaways for Long-Term Investors U.S. sales grew 83% during the first nine months. Total nine-month revenue rose 26% to $2.6 million.
seekingalpha.com IceCure Medical Ltd (ICCM) Q3 2026 Earnings Call Transcript IceCure Medical Ltd (ICCM) Q3 2026 Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Akanda (NASDAQ:AKAN) shares rose 66.8% to $3.42 during Wednesday's regular session. The market value of their outstanding shares is at $5.4 million. Cue Biopharma (NASDAQ:CUE) shares rose…
zacks.com IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.83.benzinga.com Icecure Medical Q3 EPS $(0.40) Beats $(1.16) Estimate, Sales $824.000K Miss $876.500K Estimate Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.16) by 65.52 percent. This is a 77.78 percent increase over losses of…
prnewswire.com IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States CAESAREA, Israel, Nov. 18, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that…benzinga.com IceCure Medical Receives New Patent In China For Covering A Connector Used In Its Cryogenic Technology Platform IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to
benzinga.com IceCure Medical Completes Treatment Of First Patient In Its Post-Marketing Study Evaluating ProSense Cryoablation For Local Treatment Of Low-Risk Breast Cancer First patient enrolled and treated at West Cancer Center in Tennessee, USACAESAREA, Israel, Oct. 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the
